DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04127747 (ClinicalTrials.gov)	August 18, 2020	14/10/2019	Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus	A Multicenter, Randomized Controlled Clinical Study About Efficacy and Safety of Standard Dose and Individualized Dose of Rituximab in Maintaining Remission in Patients With Moderate to Severe Systemic Lupus Erythematosus	Autoimmune Diseases	Drug: Standard dose of rituximab;Drug: Individualized dose of rituximab	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	18 Years	65 Years	All	110	Phase 4	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04127747
(ClinicalTrials.gov)

August 18, 2020

14/10/2019

Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus

A Multicenter, Randomized Controlled Clinical Study About Efficacy and Safety of Standard Dose and Individualized Dose of Rituximab in Maintaining Remission in Patients With Moderate to Severe Systemic Lupus Erythematosus

Autoimmune Diseases

Drug: Standard dose of rituximab;Drug: Individualized dose of rituximab

Second Affiliated Hospital, School of Medicine, Zhejiang University

NULL

Recruiting

18 Years

65 Years

All

110

Phase 4

China